Saliogen Therapeutics

Risk score

57

Headquarters

Flag of United States of AmericaUnited States of America

SalioGen Therapeutics is progressing potentially therapeutic genetic treatments using its Precise DNA Integration Technology (EDIT) platform, the singular genome modification technology that is derived from mammals. SalioGen is initially concentrating on delivering long-lasting, secure, and cost-effective non-viral genetic treatments to a larger number of individuals with hereditary conditions. In the future, SalioGen will also investigate the capabilities of the EDIT platform to simplify cell therapy, cell modification, and biologics production to assist an even wider range of patients in need.